Get the Stockscreener App
2.12
1.85%
-0.04
Ac Immune Sa stock is traded at $2.12, with a volume of 88,622.
It is down -1.85% in the last 24 hours and up +7.07% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.16
Open:
$2.1
24h Volume:
88,622
Relative Volume:
0.69
Market Cap:
$212.87M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-2.988
EPS:
-0.7095
Net Cash Flow:
$-68.17M
1W Performance:
-12.76%
1M Performance:
+7.07%
6M Performance:
-22.91%
1Y Performance:
-44.50%
1-Day Range:
$2.0451
$2.20
1-Week Range:
$2.0451
$2.50
52-Week Range:
$1.4299
$3.98
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.12 | 217.30M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
Is AC Immune SA stock poised for growthWeekly Trend Watch with Market Signals - Newser
Can momentum traders help lift AC Immune SAWeekly Trend Screener with Momentum Picks - Newser
How does AC Immune SA compare to its industry peersEntry Signal Report For Beginners - jammulinksnews.com
Published on: 2025-08-01 04:44:10 - Newser
Developing predictive dashboards with AC Immune SA dataWeekly Breakout Forecast with Entry Zones - Newser
When is the best time to exit AC Immune SAFree Capital Protection Trading Strategies - Newser
What markets is BPYPO expanding into Is AC Immune SA stock a good long term investment optionWealth Building Planner With Proven Results - jammulinksnews.com
Multi asset correlation models including AC Immune SADay Trading Setup Forecast with Trend Model - Newser
Will AC Immune SA stock split in the near futureReal Time Growth Signal with Smart Setup - Newser
What are analysts’ price targets for AC Immune SA in the next 12 monthsTop Growth Entry Points To Watch Now - jammulinksnews.com
What makes AC Immune SA stock price move sharplyHigh Confidence Strategy with Trend Alignment - Newser
Is AC Immune SA reversing from oversold territoryProfitable Trading Blueprint with Entry Zones - Newser
Why AC Immune SA stock attracts strong analyst attentionFree Proven Entry Plan With Low Risk Trade - Newser
Analysts Spot Bullish Divergence in AC Immune SACommunity Strategy With High Win Rate Backtested - metal.it
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance
AC Immune SA Crosses 200 Day MA — Signal or NoiseCommunity Strategy With High Win Rate Backtested - metal.it
Top Risks to Consider Before Buying AC Immune SA StockFree Entry Plan for Oversold Reversal Stocks - Newser
What institutional investors are buying AC Immune SA stockGet alerts on the hottest market movers - jammulinksnews.com
Why is AC Immune SA stock attracting strong analyst attentionCapitalize on market momentum for maximum gains - jammulinksnews.com
What is the risk reward ratio of investing in AC Immune SA stockInvest confidently with market-leading analysis - jammulinksnews.com
What is the dividend policy of AC Immune SA stockInvest smarter with data-backed trading alerts - jammulinksnews.com
AC Immune SA Stock Performance After Earnings: Historical InsightsGrowth Optimized Stock Radar - Newser
Key External Factors That Drive AC Immune SA Stock Price MovementsFree Stock Market Practical Discussion Forums - Newser
What analysts say about AC Immune SA stockConsistent high-performance stocks - PrintWeekIndia
What drives AC Immune SA stock pricePhenomenal investment performance - Autocar Professional
Is AC Immune SA a good long term investmentExceptional gains - Autocar Professional
Can AC Immune SA stock recover from recent declineHigh-yield growth strategies - jammulinksnews.com
Is AC Immune SA stock a growth or value playDynamic growth stocks - jammulinksnews.com
Published on: 2025-07-23 19:50:12 - jammulinksnews.com
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):